These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 16044664)

  • 1. The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.
    Di Napoli M; McLaughlin B
    Curr Opin Investig Drugs; 2005 Jul; 6(7):686-99. PubMed ID: 16044664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy.
    Wojcik C; Di Napoli M
    Stroke; 2004 Jun; 35(6):1506-18. PubMed ID: 15118168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the ubiquitin-proteasome system in brain ischemia: friend or foe?
    Caldeira MV; Salazar IL; Curcio M; Canzoniero LM; Duarte CB
    Prog Neurobiol; 2014 Jan; 112():50-69. PubMed ID: 24157661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases.
    Shah IM; Di Napoli M
    Cardiovasc Hematol Disord Drug Targets; 2007 Dec; 7(4):250-73. PubMed ID: 18220725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the ubiquitin proteasome system in haematological malignancies.
    Crawford LJ; Irvine AE
    Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
    Dalla Via L; Nardon C; Fregona D
    Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition during myocardial infarction.
    Yu X; Kem DC
    Cardiovasc Res; 2010 Jan; 85(2):312-20. PubMed ID: 19744947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nuclear ubiquitin-proteasome system: visualization of proteasomes, protein aggregates, and proteolysis in the cell nucleus.
    von Mikecz A; Chen M; Rockel T; Scharf A
    Methods Mol Biol; 2008; 463():191-202. PubMed ID: 18951170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
    Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB
    Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.
    Chen D; Dou QP
    Curr Protein Pept Sci; 2010 Sep; 11(6):459-70. PubMed ID: 20491623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of deubiquitinating enzyme inhibitors.
    Colland F
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):137-43. PubMed ID: 20074048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
    Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
    Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
    Frezza M; Schmitt S; Dou QP
    Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition in multiple myeloma: therapeutic implication.
    Chauhan D; Hideshima T; Anderson KC
    Annu Rev Pharmacol Toxicol; 2005; 45():465-76. PubMed ID: 15822185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop.
    Steffen J; Seeger M; Koch A; Krüger E
    Mol Cell; 2010 Oct; 40(1):147-58. PubMed ID: 20932482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the ubiquitin proteasome system in lymphoma.
    Suh KS; Tanaka T; Sarojini S; Nightingale G; Gharbaran R; Pecora A; Goy A
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):306-22. PubMed ID: 23541070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases.
    Chitra S; Nalini G; Rajasekhar G
    Int J Rheum Dis; 2012 Jun; 15(3):249-60. PubMed ID: 22709487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for the identification of ubiquitin ligase inhibitors.
    Goldenberg SJ; Marblestone JG; Mattern MR; Nicholson B
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):132-6. PubMed ID: 20074047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy.
    Brahimi-Horn C; Pouysségur J
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):115-23. PubMed ID: 15661562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.
    Csizmadia V; Csizmadia E; Silverman L; Simpson C; Raczynski A; O'Brien L; Gallacher M; Cardoza K; Kadambi VJ; Fedyk ER; Alden CL
    Vet Pathol; 2010 Mar; 47(2):358-67. PubMed ID: 20124009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.